Preferred Label : Anti-SIRP-alpha Antibody BR105;
NCIt synonyms : SIRPalpha-targeting Antibody BR105; Anti-SIRPa Antibody BR105;
NCIt definition : An antibody targeting human signal-regulatory protein alpha (SIRPa; CD172a), with
potential immune checkpoint inhibitory, phagocytosis-inducing and antineoplastic activities.
Upon administration, anti-SIRPa antibody BR105 targets and binds to SIRPa, a cell
surface protein expressed on macrophages, thereby blocking the interaction between
SIRPa and cluster of differentiation 47 (CD47) expressed on tumor cells. This prevents
CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of
phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin
(CRT), which is specifically expressed on the surface of tumor cells, to low-density
lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages, and results
in macrophage activation and the specific phagocytosis of tumor cells. SIRPa, also
known as tyrosine-protein phosphatase non-receptor type substrate 1, mediates negative
regulation of phagocytosis, mast cell activation and dendritic cell activation. CD47,
also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA)
expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed on
the surface of a variety of cancer cells. Expression of CD47, and its interaction
with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells
from phagocytosis, which allows cancer cells to proliferate.;
Molecule name : BR 105; BR-105;
NCI Metathesaurus CUI : CL1792339;
Origin ID : C187653;
UMLS CUI : C5706422;
- Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target